We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

417A:TSEBLUE ZONES HOLDINGS CO. LTD. Analysis

Data as of 2026-06-12 - not real-time

¥1,769.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Blue Zones Holdings trades around ¥1,769, roughly 32% above its DCF-derived fair value of ¥1,342, suggesting the stock is currently overvalued. The technical picture is mixed: RSI sits at a neutral 52.9, the MACD histogram is positive (+9.95) indicating short‑term bullish momentum, yet the trend is classified as neutral and volume is decreasing, which tempers optimism. Fundamentals show robust 14.6% revenue growth and a respectable dividend yield of 1.81%, but margins are thin (operating margin slightly negative) and the payout ratio is high at 95%, raising concerns about dividend sustainability. The company carries a debt‑to‑equity ratio of 44, modest beta near zero and a 30‑day volatility of about 21%, reflecting low systematic risk but notable price swings. The consumer‑defensive grocery sector is typically low‑risk, yet regulatory and demographic pressures in Japan add a medium layer of uncertainty. With the market sentiment tilted toward "Extreme Greed" (fear‑greed index 89.86), investors should be cautious and consider the overvaluation and dividend risks before taking positions.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price above fair value (~32% premium)
  • Neutral technical trend with decreasing volume
  • High dividend payout ratio (95%)

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong revenue growth (14.6%) but thin operating margins
  • Elevated debt‑to‑equity (44) and modest cash generation
  • Sector stability offset by regulatory and demographic headwinds

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Consumer‑defensive grocery exposure provides defensive footing
  • Dividend yield attractive but sustainability questionable
  • Current overvaluation may require price correction before upside

Key Metrics & Analysis

Financial Health

Revenue Growth14.60%
Profit Margin2.90%
P/E Ratio15.3
ROE12.41%
ROA5.71%
Debt/Equity44.02
P/B Ratio1.8
Op. Cash Flow¥47.1B
Free Cash Flow¥12.7B

Technical Analysis

TrendNeutral
RSI52.9
Support¥1,664.00
Resistance¥1,814.00
MA 20¥1,739.15
MA 50¥1,796.37
MA 200¥1,773.49
MACDBullish
VolumeDecreasing
Fear & Greed Index89.86

Valuation

Fair Value¥1,342.49
Target Price¥2,100.00
Upside/Downside18.71%
GradeOvervalued
TypeBlend
Dividend Yield1.81%

Risk Assessment

Beta-0.01
Volatility20.97%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.